Literature DB >> 29293375

Long-term follow-up after childhood cancer in France supported by the SFCE-force and weakness-current state, results of a questionnaire and perspectives.

Charlotte Demoor-Goldschmidt1,2, Marie-Dominique Tabone3, Valérie Bernier4, Florent de Vathaire1, Claire Berger5.   

Abstract

OBJECTIVE: The survival rate of children treated for cancer is currently about 80% at 5 years and we estimate that about 50,000 adults in France have survived childhood cancer. In 2011, there was a call for projects relating to long-term follow-up (LTFU), which led to several studies being conducted. Five years later, we sent a questionnaire to present LTFU in France and describe its strengths and weaknesses and to establish appropriate steps that should be taken.
METHODS: A questionnaire was sent by email to all the members of the French Society of Childhood Cancers in spring 2016. The study involved 44 centres/hospitals with a Paediatric Oncology Department.
RESULTS: 54 answers were analysed, provided by 31/44 (70%) centres working together with the French Society of Childhood Cancers. Screening is the main objective of LTFU care (90%). The main difficulties that arose were: lack of sufficient time to devote to this activity (57%), difficulties contacting adult childhood cancer survivors (aCCSs) (26%), aCCSs who ultimately did not show up to the consultation (19%), cost (15%), and lack of organization (13%). Seven LTFU programmes were identified: two regional organizations (Rhône Alpes and Grand Ouest), four centre-size organizations, and one national study (involving 15 Haematology Centres) relating to Child and Adolescent Leukaemia.
CONCLUSION: LTFU is a major concern for French centres specialized in paediatric oncology. Organization is not well defined and difficulties still arise (Who are the best care providers? What frequency of care is most appropriate? etc.). Advances in knowledge: LTFU focused on health problems (physical, psychological, social, economic issues) that affect CCSs is needed to ensure that these patients regain the most optimal physical and emotional health possible. Practitioners suggest different ways to improve LTFU, such as national co-operation with Epidemiology Registers to promote homogenous LTFU care.

Entities:  

Mesh:

Year:  2018        PMID: 29293375      PMCID: PMC5966008          DOI: 10.1259/bjr.20170819

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  53 in total

Review 1.  Long-term follow-up following childhood cancer: maximising the contribution from nursing.

Authors:  F Gibson; L Soanes
Journal:  Eur J Cancer       Date:  2001-10       Impact factor: 9.162

Review 2.  Developing international consensus for late effects screening and guidance.

Authors:  Rod Skinner; Kevin C Oeffinger
Journal:  Curr Opin Support Palliat Care       Date:  2013-09       Impact factor: 2.302

Review 3.  Models of cancer survivorship health care: moving forward.

Authors:  Kevin C Oeffinger; Keith E Argenbright; Gill A Levitt; Mary S McCabe; Paula R Anderson; Emily Berry; Jane Maher; Janette Merrill; Dana S Wollins
Journal:  Am Soc Clin Oncol Educ Book       Date:  2014

Review 4.  Risk-based health care, the cancer survivor, the oncologist, and the primary care physician.

Authors:  Mary S McCabe; Ann H Partridge; Eva Grunfeld; Melissa M Hudson
Journal:  Semin Oncol       Date:  2013-12       Impact factor: 4.929

5.  Passport for care: implementing the survivorship care plan.

Authors:  Marc E Horowitz; Michael Fordis; Susan Krause; Julie McKellar; David G Poplack
Journal:  J Oncol Pract       Date:  2009-05       Impact factor: 3.840

6.  Thyroid adenomas after solid cancer in childhood.

Authors:  Nadia Haddy; Chiraz El-Fayech; Catherine Guibout; Elisabeth Adjadj; Cécile Thomas-Teinturier; Odile Oberlin; Cristina Veres; Hélène Pacquement; Angela Jackson; Martine Munzer; Tan Dat N'Guyen; Pierre-Yves Bondiau; Delphine Berchery; Anne Laprie; André Bridier; Dimitri Lefkopoulos; Martin Schlumberger; Carole Rubino; Ibrahima Diallo; Florent de Vathaire
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-06-05       Impact factor: 7.038

Review 7.  Cancer survivorship practices, services, and delivery: a report from the Children's Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees.

Authors:  Debra Eshelman-Kent; Karen E Kinahan; Wendy Hobbie; Wendy Landier; Steve Teal; Debra Friedman; Rajaram Nagarajan; David R Freyer
Journal:  J Cancer Surviv       Date:  2011-09-06       Impact factor: 4.442

8.  [French organization of paediatric radiation treatment: Results of a survey conducted by the radiotherapy Committee of the French Society of Paediatric Cancers (SFCE)].

Authors:  C Demoor-Goldschmidt; L Claude; C Carrie; S Bolle; S Helfre; C Alapetite; A Jouin; L Padovani; A Ducassou; C Vigneron; É Le Prisé; A Huchet; D Stefan; C Kerr; T-D Nguyen; G Truc; S Chapet; P-Y Bondiau; B Coche; X Muracciole; A Laprie; G Noël; J Leseur; J-L Habrand; H Potet; A Ruffier; S Supiot; M-A Mahé; V Bernier
Journal:  Cancer Radiother       Date:  2016-07-13       Impact factor: 1.018

9.  Health-related quality of life in survivors of childhood cancer: the role of chronic health problems.

Authors:  Corina S Rueegg; Micol E Gianinazzi; Johannes Rischewski; Maja Beck Popovic; Nicolas X von der Weid; Gisela Michel; Claudia E Kuehni
Journal:  J Cancer Surviv       Date:  2013-06-20       Impact factor: 4.442

10.  Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study.

Authors:  Melissa M Hudson; Ann C Mertens; Yutaka Yasui; Wendy Hobbie; Hegang Chen; James G Gurney; Mark Yeazel; Christopher J Recklitis; Neyssa Marina; Leslie R Robison; Kevin C Oeffinger
Journal:  JAMA       Date:  2003-09-24       Impact factor: 157.335

View more
  1 in total

Review 1.  Review of risk factors of secondary cancers among cancer survivors.

Authors:  Charlotte Demoor-Goldschmidt; Florent de Vathaire
Journal:  Br J Radiol       Date:  2018-09-12       Impact factor: 3.039

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.